http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Dyne Therapeutics Inc. (DYN) Announces FDA Clearance of Clinical Trial Application for DYNE-101
-
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
-
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
-
Dyne Therapeutics Inc. (DYN) Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
-
Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
-
Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
-
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
-
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
-
Dyne Therapeutics Inc. (DYN) Presents New In Vivo Data from DYNE-101
-
Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown
-
Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown
-
Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
-
Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
-
selfologi Chooses Digital Technology Consulting Partner Grid Dynamics to Launch Its Cosmetic Treatment Platform
-
Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
-
Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
-
Dyne Therapeutics Inc. (DYN) Appoints Carlo Incerti to its Board
-
Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors
-
Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors
-
Dyne Therapeutics Inc. (DYN) Announces FDA Places Clinical Hold on IND Application for DYNE-251
-
Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy
-
Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy
-
Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Dyne Therapeutics (DYN) Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for DMD
-
Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy
-
Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy
-
Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
-
Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
-
Dyne Therapeutics Inc. (DYN) Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs
-
Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day
-
Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day
-
Dyne Therapeutics (DYN) Presents New In Vivo Data for its DMD Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression
-
Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophi
-
Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophi
-
Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021
-
Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021
-
Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference
-
Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference
-
Dyne Therapeutics (DYN) Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During WMS
-
Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress
-
Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress
-
Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
-
Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
-
Dyne Therapeutics Inc. (DYN) Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
-
Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
-
Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
-
Dyne Therapeutics Announces Chief Scientific Officer Transition
-
Dyne Therapeutics Announces Chief Scientific Officer Transition
-
Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference
